[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"HJN Sverige AB\u002FNeko Health\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":156},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,71,96,116,138],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":25,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100620603","non-invasive-microvascular-assessment-in-individuals-at-high-risk-of-cardiovascular-disease-from-the-scapis2-study-100620603",false,"NCT07359768","Non-invasive Microvascular Assessment in Individuals at High Risk of Cardiovascular Disease From the SCAPIS2 Study","SCAPIS 2 - Spectrum Study -CVD Risk Based on Microvascular Dysfunction","Inclusion Criteria:\n\n* Participated in the SCAPIS baseline (SCAPIS 1 study, 10 years ago)\n* Cohort specific inclusion criteria apply, as stated in 'groups' section\n* Has been invited to SCAPIS 2 core Singed informed consent to SCAPIS 2 core\n\nExclusion Criteria:\n\n* Scarring, tattoos, or amputations that preclude device examination\n* Cohort specific exclusion criteria apply, as stated in 'groups' section","ALL",{"count":18,"type":19},900,"ESTIMATED","OBSERVATIONAL","Microvascular dysfunction, particularly endothelial dysfunction, is increasingly recognized as a key mechanism underlying various cardiovascular diseases (CVD), including heart failure, ischemic heart disease, atherosclerosis, stroke, dementia, and kidney failure. Chronic low-grade inflammation linked to metabolic syndrome may further drive systemic microvascular impairment. Early detection of these subclinical processes using non-invasive assessments could facilitate timely interventions to prevent disease progression.\n\nSCAPIS 2 Spectrum is a prospective observational sub-study of the Swedish Cardiopulmonary Bioimage Study (SCAPIS-2), recruiting approximately 900 subjects aged 60-75 years. The study is organized into five arms-obstructive coronary artery disease (O-CAD), angina with nonobstructive coronary arteries (ANOCA), metabolic syndrome with diabetes, left ventricular systolic dysfunction, and left ventricular diastolic dysfunction-each defined by specific inclusion and exclusion criteria. Participants will undergo a comprehensive microvascular assessment using investigational devices (including Perimed Periflux EPOS, PeriCam MultiFlow, and TCI P4) alongside stress cardiac magnetic resonance imaging (stress-CMR) for cardiac-specific evaluation.",[23,24],"Cardiovascular Diseases","Microvascular Complications",[26,27,28,29,30,31,32],"microvascular","non-invasive","microcirculation","spatial frequency domain imaging","cardiac magnetic resonance imaging","laser speckle contrast imaging","laser doppler flowmetry","RECRUITING","2026-01-13",{"date":36,"type":37},"2026-01-22","ACTUAL",{"date":39,"type":37},"2024-03-18",{"date":41,"type":19},"2026-12-29",{"name":43,"class":44},"HJN Sverige AB\u002FNeko Health","INDUSTRY",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":45},"100593020","scapis-2-cardio---vibrometer-based-pulse-wave-analysis-and-cvd-risk-assessment-100593020","NCT07001007","SCAPIS 2 Cardio - Vibrometer Based Pulse Wave Analysis and CVD Risk Assessment","Inclusion Criteria:\n\n* Subjects already included in the main \u002F general SCAPIS 2 study at Danderyd Hospital in Stockholm, and of which has also participated in the echocardiography examination\n\nExclusion Criteria:\n\n* Patients unable to provide an informed consent",true,"58 Years","72 Years",{"count":56,"type":19},1600,"This clinical investigation will evaluate a novel contactless technology for assessing arterial stiffness and pulse wave characteristics and explore its potential in assessment of coronary artery disease, aortic stenosis and heart failure, in a population-based sample aged 58-72 years.\n\nIt will be the first in clinical setting, pilot stage, observational investigation to evaluate the clinical safety, performance and diagnostic accuracy of Cardio P4, a laser-doppler vibrometry (LDV) and microwave radar-based device.",[59,60,61,62],"Coronary Arterial Disease (CAD)","Arterial Stiffness","Aortic Valve Disease","Heart Failure","2025-05-30",{"date":65,"type":37},"2025-06-03",{"date":67,"type":37},"2024-07-01",{"date":69,"type":19},"2026-06",{"name":43,"class":44},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":52,"sex":16,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100591729","vibrometer-based-pulse-wave-analysis-for-arterial-stiffness-and-ischemic-heart-disease-risk-assessment-100591729","NCT06984211","Vibrometer Based Pulse Wave Analysis for Arterial Stiffness and Ischemic Heart Disease Risk Assessment","Cardio Alpha - Vibrometer Based Pulse Wave Analysis for Arterial Stiffness and Ischemic Heart Disease Risk Assessment","Inclusion criteria:\n\n* Adult patients that are part of the regular healthcare patient flow at the investigational sites, or as separately invited to participate in this investigation.\n* Patients with signed informed consent\n\nExclusion criteria:\n\n* Cognitive impairment\n* Patients unable to understand the oral and written study information in Swedish or English\n* Other severe disorder or terminal disease, e.g. infection\u002Fsepsis, severe COPD or metastatic cancers.\n* Patients unable to provide an informed consent","18 Years",{"count":80,"type":19},8000,"This clinical investigation will evaluate a novel contactless technology for assessing arterial stiffness and explore its potential in assessment of risk for and development of cardiovascular disease.\n\nThe main aims of the study are:\n\n1. To assess device and method performance for assessment of arterial stiffness and cardiovascular risk, on a prospective primary care cohort.\n2. To see if precision may be added in CVD risk assessment through a multi-modal approach, combining data on macro- and micro-circulatory function.",[83,84,85,62,86],"Hypertension","Ischemic Heart Disease","Valvular Heart Disease","Diabetes","2025-05-19",{"date":89,"type":37},"2025-05-22",{"date":91,"type":37},"2023-02-01",{"date":93,"type":19},"2026-02-01",{"name":43,"class":44},3,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":52,"sex":16,"minAge":78,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":45},"100592112","the-mind-study---microangiopathy-in-diabetes-100592112","NCT06989190","The MIND Study - Microangiopathy IN Diabetes","Phase 1: Severe Diabetic Complications (50 patients)\n\nInclusion Criteria:\n\n* Severe type 1 diabetes (microangiopathy \u002F diabetic feet), severe angiopathy defined as proliferative retinopathy, macroalbuminuria, and kidney failure with at least CKD-class 3B and severe neuropathy with or without foot ulcers.\n* Age range: primarily 18-45 years, if not sufficient number of subjects can be found, then 18-60 years span is considered\n\nPhase 2: Scale of severity. In phase 2, patients are included with a broad range of severity levels. Patients with diabetes type 1 will be included.\n\nInclusion criteria:\n\n* Age range: 18-45 years (younger patients are targeted for focus on microvascular complications, rather than age-related cardiovascular disease)\n* Patient with no microangiopathy, except for simplex or background retinopathy, which is in an early and reversible state (group a), 100 patients.\n* Patient with mild microangiopathy, mild-moderate non-proliferative retinopathy and\u002For microalbuminuria and\u002For early signs of neuropathy (group b), 100 patients.\n* Patient with moderate microangiopathy. moderate non-proliferative retinopathy or proliferative retinopathy, macroalbuminuria or kidney failure (defined as estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73 m2 body surface) up to CKD-class 3A, and manifest neuropathy, (group c), 50 patients.\n\nHealthy controls:\n\n\\- Healthy control matched to the type 1 diabetes patients in age and gender, with no known risk of increased cardiovascular disease.\n\nExclusion Criteria:\n\n* Patients unable to understand patient information due to cognitive impairment\n* Patients unable to understand patient information due to language barriers\n* Ongoing acute infection or inflammatory condition\n* Pregnant or breastfeeding women\n* Patients with damaged and\u002For scarred tissue in the areas of interest for the investigational or comparator devices","60 Years",{"count":104,"type":19},400,"This clinical investigation will evaluate two contactless optical devices based on spatial frequency domain and laser speckle technology for quantification of the skin micro-circulation in patients with diabetes mellitus type 1.",[107],"Diabetes Type 1","2025-05-16",{"date":110,"type":37},"2025-05-25",{"date":112,"type":37},"2023-12-19",{"date":114,"type":19},"2026-12",{"name":43,"class":44},{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":52,"sex":16,"minAge":78,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":134,"startDateStruct":135,"completionDateStruct":136,"leadSponsor":137,"locationsCount":95},"100592114","multi-modal-quantitative-imaging-of-the-skin-100592114","NCT06989216","Multi-modal Quantitative Imaging of the Skin","DermaFlow Alpha - Multi-modal Quantitative Imaging of the Skin","DermaFlow","Inclusion criteria:\n\n* Adult patients that are part of the regular healthcare patient flow at the investigational sites, or as separately invited to participate in this investigation.\n* Patients with signed informed consent\n\nExclusion criteria:\n\n* Cognitive impairment\n* Patients unable to understand the oral and written study information in Swedish or English\n* Other severe disorder or terminal disease\n* Patients unable to provide an informed consent\n* Patients not able to keep balance, while standing up with closed eyes, without any aid\n* Claustrophobic patients",{"count":80,"type":19},"This clinical trial is about evaluating the suitability of multi-modal imaging technology, which covers virtually the entire body, to evaluate the possibility of screening and early detection of disease.",[127,128,129,130,131,132,133],"Skin Cancer","Skin Diseases","Atopic Dermatitis","Psoriasis","Raynaud Disease","Diabetic Foot","Peripheral Arterial Disease",{"date":110,"type":37},{"date":91,"type":37},{"date":93,"type":19},{"name":43,"class":44},{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":52,"sex":16,"minAge":78,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":152,"completionDateStruct":153,"leadSponsor":155,"locationsCount":95},"100591103","non-invasive-imaging-for-in-vivo-quantification-of-skin-composition-and-structure-100591103","NCT06976073","Non-invasive Imaging for In-vivo Quantification of Skin Composition and Structure","Spectrum1","Inclusion Criteria:\n\n* Adult patients part of the regular healthcare patient flow at the investigational sites, or as separately invited to participate in this investigation.\n* Patients with signed informed consent\n\nExclusion Criteria:\n\n* Cognitive impairment\n* Patients unable to understand the oral and written study information in Swedish or English\n* Other severe disorder or terminal disease\n* Patients unable to provide an informed consent\n* Patient´s with damaged, scarred or non-intact skin within the skin area of interest.",{"count":80,"type":19},"The goal of this clinical investigation is to explore a non-invasive technology for measuring the microcirculatory structure, composition and function in patients from a primary care population.\n\nThe main aims are:\n\n1. To evaluate the robustness of the technology for assessment of the molecular composition and structure of the skin tissue and microcirculatory function, on a prospective primary care population.\n2. To evaluate the device and method on its capability to detect deficiencies in circulation, compared with existing reference systems with similar characteristics for patients with known cardiovascular disease risk and\u002For diabetes.",[148,132,133,127,149],"Diabetes Mellitus, Type 2","Cardiovascular Disease Risk","2025-05-08",{"date":108,"type":37},{"date":91,"type":37},{"date":154,"type":19},"2026-01-01",{"name":43,"class":44},""]